← Human Trials & Peer-Reviewed Studies
Efficacy and Safety of Liraglutide [amount hidden] in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
Plain-language guide to PMID 32139381 (2020): double-blind randomized controlled trial study of Liraglutide.
Key Facts
- PMID
- 32139381
- Journal
- Diabetes care
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Garvey WT et al. (10 authors)
- DOI
- 10.2337/dc19-1745
- Registered trial
- NCT02963922
What This Study Did, in Plain Language
What Was Tested
Researchers studied Liraglutide in this randomized controlled trial publication.
Most individuals with type 2 diabetes also have obesity, and treatment with some diabetes medications, including insulin, can cause further weight gain.
No approved chronic weight management medications have been prospectively investigated in individuals with overweight or obesity and insulin-treated type 2 diabetes.
Who Took Part
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.
Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.
More than one site took part, so the participants came from several places.
Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs.
What Was Measured
The subject headings attached to it are Adiposity, Behavior Therapy, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Glycated Hemoglobin and Insulin.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Liraglutide.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2020 (Diabetes care), a journal based in United States.
More context: the Liraglutide compound page.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.